GlassScriptPhysician profile
Emmanuel Mantilla
NPI 1477757730
$9,464.74
in general payments reported to CMS, 2019-2025
23 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $2,793 · 2021: $2,046 · 2022: $766 · 2023: $1,247 · 2024: $1,003 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.71 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $4,107.95 | 2019-2025 | Optune, Optune Gio, Optune Lua (Novottf-200t) |
| Livanova USA, INC. | $1,462.46 | 2020-2022 | |
| Gt Medical Technologies, INC | $844.37 | 2021-2025 | Gammatile, Gammatile |
| Ucb, INC. | $564.18 | 2019-2025 | Briviact, Fintepla |
| Bayer Healthcare Pharmaceuticals INC. | $525.00 | 2023 | |
| Monteris Medical Corporation | $382.32 | 2022-2025 | Neuroblate |
| Sk Life Science, INC. | $357.28 | 2023-2025 | Xcopri |
| Servier Pharmaceuticals LLC | $263.86 | 2024-2025 | |
| Abbvie INC. | $218.10 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $208.78 | 2024-2025 | |
| Tempus Ai, INC | $112.71 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $88.92 | 2023-2024 | Welireg |
| Springworks Therapeutics, INC. | $73.22 | 2025 | Gomekli, Ogsiveo |
| Novartis Pharmaceuticals Corporation | $71.25 | 2021-2022 | |
| Immunitybio, INC. | $42.32 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $37.85 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $24.46 | 2024 | Sancuso |
| Telix Pharmaceuticals | $24.43 | 2024 | Illuccix |
| Neurelis, INC. | $22.24 | 2025 | Valtoco |
| Pfizer INC. | $16.98 | 2024 | |
| Genzyme Corporation | $16.06 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Mantilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.